Diabetology International

, Volume 5, Issue 1, pp 36–42 | Cite as

Factors associated with glycemic variability in Japanese patients with diabetes

  • Chihiro Tanaka
  • Yoshifumi SaishoEmail author
  • Kumiko Tanaka
  • Kinsei Kou
  • Masami Tanaka
  • Shu Meguro
  • Junichiro Irie
  • Rie Jo
  • Toshihide Kawai
  • Hiroshi Itoh
Original Article


The aim of this study was to clarify determinants of glycemic variability in Japanese patients with diabetes. We performed continuous glucose monitoring (CGM) for 2–4 days in 88 patients with diabetes admitted to our hospital for poor glycemic control (20 with type 1 and 68 with type 2 diabetes). Glycemic variability was assessed by standard deviation (SD) of glucose and mean amplitude of glycemic excursions (MAGE) calculated from CGM data, and its relations to clinical parameters were investigated. Beta-cell function was assessed by serum C-peptide immunoreactivity (CPR) to glucose ratio (CPR index). As a result, glycemic variability was significantly greater in patients with type 1 diabetes than in those with type 2 diabetes. In all patients, the glycated albumin to HbA1c ratio (GA/HbA1c) was positively correlated and the postprandial CPR index was negatively correlated with SD and MAGE (both p < 0.05). In patients with type 2 diabetes, age, diabetes duration, and GA/HbA1c were significantly positively correlated with SD and MAGE, while multivariate analysis suggested that age and diabetes duration are the major determinants of glycemic variability. In conclusion, while glycemic variability was greater in patients with type 1 diabetes than those with type 2 diabetes, age, diabetes duration, GA/HbA1c, and beta-cell function were associated with glycemic variability in Japanese patients with diabetes.


Glycemic variability Glycated albumin Beta-cell function Age Type 2 diabetes Continuous glucose monitoring 



Continuous glucose monitoring


C-peptide immunoreactivity


Glycated albumin


Oral glucose tolerance test


Self-monitoring of blood glucose


Standard deviation


Mean amplitude of glycemic excursions


National Glycohemoglobin Standardization Program


Glucagon-like peptide-1


Continuous subcutaneous insulin infusion



The authors thank Dr. Wendy Gray for editing the manuscript.

Conflict of interest

The authors have no conflict of interest.


  1. 1.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.PubMedCrossRefGoogle Scholar
  4. 4.
    Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRefGoogle Scholar
  6. 6.
    The DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405.CrossRefGoogle Scholar
  7. 7.
    Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Saisho Y, Kou K, Tanaka K, Abe T, Kurosawa H, et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J. 2011;58:315–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.Google Scholar
  13. 13.
    Saisho Y, Tanaka K, Abe T, Shimada A, Kawai T, et al. Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int. 2011;2:146–53.CrossRefGoogle Scholar
  14. 14.
    Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. 2008;55:503–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Suwa T, Ohta A, Matsui T, Koganei R, Kato H, et al. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J. 2010;57:135–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Saisho Y, Tanaka K, Abe T, Shimada A, Kawai T, et al. Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis. Endocr J. 2012;59:187–95.PubMedCrossRefGoogle Scholar
  17. 17.
    Sartore G, Chilelli NC, Burlina S, Stefano PD, Piarulli F et al. The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM). Acta Diabetol. 2012;49:S153–60.Google Scholar
  18. 18.
    Greven WL, Beulens JW, Biesma DH, Faiz S, de Valk HW. Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study. Diabetes Technol Ther. 2010;12:695–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ogawa A, Hayashi A, Kishihara E, Yoshino S, Takeuchi A, et al. New indices for predicting glycaemic variability. PLoS ONE. 2012;7:e46517.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32:1058–62.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Matsumoto H, Murase-Mishiba Y, Yamamoto N, Sugitatsu-Nakatsukasa S, Shibasaki S, et al. Glycated albumin to glycated hemoglobin ratio is a sensitive indicator of blood glucose variability in patients with fulminant type 1 diabetes. Intern Med. 2012;51:1315–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Monnier L, Mas E, Ginet C, Michel F, Villon L, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2006;5:27.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis. 2009;206:540–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Song SO, Kim KJ, Lee BW, Kang ES, Cha BS et al. Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis. 2012;225:450–5.Google Scholar
  26. 26.
    U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58.CrossRefGoogle Scholar
  27. 27.
    Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Saisho Y, Kou K, Tanaka K, Abe T, Shimada A, et al. Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes. Acta Diabetol. 2013 [Epub ahead of print].Google Scholar
  29. 29.
    Saisho Y, Kou K, Tanaka K, Abe T, Shimada A, et al. Association between beta cell function and future glycemic control in patients with type 2 diabetes. Endocr J. 2013;60:517–23.Google Scholar

Copyright information

© The Japan Diabetes Society 2013

Authors and Affiliations

  • Chihiro Tanaka
    • 1
  • Yoshifumi Saisho
    • 1
    Email author
  • Kumiko Tanaka
    • 1
  • Kinsei Kou
    • 1
  • Masami Tanaka
    • 1
  • Shu Meguro
    • 1
  • Junichiro Irie
    • 1
  • Rie Jo
    • 1
  • Toshihide Kawai
    • 1
  • Hiroshi Itoh
    • 1
  1. 1.Department of Internal MedicineKeio University School of MedicineTokyoJapan

Personalised recommendations